Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Puja Sapra

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Pharmacology & Therapeutics|March 20, 2013
Monoclonal antibody-based therapies in cancer: advances and challengesPuja Sapra, Boris Shor
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2004
Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopesPuja Sapra, Theresa M Allen
Cancer Research|December 25, 2002
Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugsPuja Sapra, Theresa M Allen
Expert Review of Clinical Pharmacology|August 28, 2013
Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugatesPuja Sapra, Alison Betts, Joseph Boni
Seminars in Oncology|December 3, 2014
The next generation of antibody drug conjugatesFiona Mack, Michael Ritchie, Puja Sapra
Cellular & Molecular Biology Letters|July 5, 2002
Use of the post-insertion method for the formation of ligand-coupled liposomesTheresa M Allen, Puja Sapra, Elaine Moase
Molecular Immunology|October 12, 2014
Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignanciesBoris Shor, Hans-Peter Gerber, Puja Sapra
Cellular & Molecular Biology Letters|October 16, 2002
Use of the post-insertion method for the formation of ligand-coupled liposomesTheresa M Allen, Puja Sapra, Elaine Moase
Current Drug Delivery|November 25, 2005
Ligand-targeted liposomes for cancer treatmentPuja Sapra, Pradeep Tyagi, Theresa M Allen
Biochemical Pharmacology|August 4, 2012
Advances in bispecific biotherapeutics for the treatment of cancerChad May, Puja Sapra, Hans-Peter Gerber
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Pharmacology & Therapeutics|March 20, 2013
Monoclonal antibody-based therapies in cancer: advances and challengesPuja Sapra, Boris Shor
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2004
Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopesPuja Sapra, Theresa M Allen
Cancer Research|December 25, 2002
Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugsPuja Sapra, Theresa M Allen
Expert Review of Clinical Pharmacology|August 28, 2013
Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugatesPuja Sapra, Alison Betts, Joseph Boni
Seminars in Oncology|December 3, 2014
The next generation of antibody drug conjugatesFiona Mack, Michael Ritchie, Puja Sapra
Cellular & Molecular Biology Letters|July 5, 2002
Use of the post-insertion method for the formation of ligand-coupled liposomesTheresa M Allen, Puja Sapra, Elaine Moase
Molecular Immunology|October 12, 2014
Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignanciesBoris Shor, Hans-Peter Gerber, Puja Sapra
Cellular & Molecular Biology Letters|October 16, 2002
Use of the post-insertion method for the formation of ligand-coupled liposomesTheresa M Allen, Puja Sapra, Elaine Moase
Current Drug Delivery|November 25, 2005
Ligand-targeted liposomes for cancer treatmentPuja Sapra, Pradeep Tyagi, Theresa M Allen
Biochemical Pharmacology|August 4, 2012
Advances in bispecific biotherapeutics for the treatment of cancerChad May, Puja Sapra, Hans-Peter Gerber
Pageof 6